

August 22, 2013

08:30 am CET

Skanska signs contract for next phase of Novartis Cambridge Campus Expansion Project, USA, worth USD 130 M, about SEK 848 M

Skanska has signed a contract for the next phase of work with existing client Novartis for the expansion of its pharmaceutical research campus located in Cambridge, MA, USA. The contract value is USD 130 M, about SEK 848 M, which will be included in order bookings for Skanska USA Building for the third quarter of 2013.

Work on the project began in 2012 and is scheduled to be completed in 2015.

Skanska USA is one of the leading development and construction companies in the country, consisting of four business units: Skanska USA Building, which specializes in building construction; Skanska USA Civil, specialized in civil infrastructure; Skanska Infrastructure Development, which develops public-private partnerships; and Skanska Commercial Development, which develops commercial projects in select U.S. markets. Headquartered in New York, Skanska USA has approximately 8,300 employees and its 2012 revenues were SEK 37.3 billion.

For further information, please contact:

Beth Miller, Communications Manager, Skanska USA,
tel +917 656 5883

Pontus Winqvist, Senior Vice President Investor Relations,
Skanska AB, tel +46 10 448 88 51

Direct line for media: +46 10 448 88 99

This and previous releases can also be found at www.skanska.com

Skanska AB may be required to disclose the information provided herein pursuant to the Securities Markets Act.

Skanska is one of the world's leading project development and construction groups with expertise in construction, development of commercial and residential premises, and public-private partnership projects. Based on its global green experience, Skanska aims to be the client's first choice for green solutions. The group currently has 57,000 employees in selected home markets in Europe, the US and Latin America. Skanska's sales in 2012 totalled SEK 132 billion.